<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432022000100010</article-id>
<article-id pub-id-type="doi">10.7399/fh.11776</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Rivaroxabán e inhibidores selectivos de la recaptación de serotonina: análisis comparativo del riesgo de sangrado]]></article-title>
<article-title xml:lang="en"><![CDATA[Rivaroxaban and selective serotonin reuptake inhibitors: bleeding risk resulting from their concomitant use]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bruni-Montero]]></surname>
<given-names><![CDATA[Miguel Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caro-Teller]]></surname>
<given-names><![CDATA[José Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Ramos]]></surname>
<given-names><![CDATA[José Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosas-Espinoza]]></surname>
<given-names><![CDATA[Cristian]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Canales-Siguero]]></surname>
<given-names><![CDATA[Dolores]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferrari-Piquero]]></surname>
<given-names><![CDATA[José Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario 12 de Octubre Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Enfermera Isabel Zendal Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2022</year>
</pub-date>
<volume>46</volume>
<numero>1</numero>
<fpage>10</fpage>
<lpage>14</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432022000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432022000100010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432022000100010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: La combinación de rivaroxabán e inhibidores selectivos de la recaptación de serotonina presenta un riesgo de interacción farmacodinámica y farmacocinética que depende del tipo de inhibidor selectivo de la recaptación de serotonina empleado, ya que algunos son inhibidores del citocromo p450, mientras que otros no lo son. El objetivo del presente estudio fue evaluar con datos de vida real si el tipo de inhibidor selectivo de la recaptación de serotonina utilizado influye en la frecuencia y en la gravedad de sangrado en pacientes anticoagulados con rivaroxabán.  Método: Estudio observacional, longitudinal, retrospectivo y unicéntrico, realizado entre enero de 2016 y febrero de 2020 en pacientes &#8805; 18 años que recibían rivaroxabán, en indicaciones autorizadas y financiadas, y que estaban siendo tratados concomitantemente con inhibidores selectivos de la recaptación de serotonina. Se establecieron dos cohortes en función del inhibidor selectivo de la recaptación de serotonina coadministrado: inhibidores del CYP3A4 (grupo 1) &#8212;sertralina, fluoxetina y paroxetina&#8212;, y no inhibidores del CYP3A4 (grupo 2) &#8212;citalopram y escitalopram&#8212;. Se analizaron los eventos hemorrágicos, la gravedad del sangrado, la dosis diaria de rivaroxabán y la medicación concomitante que pudiese influir en el riesgo de sangrado.  Resultados: Se incluyeron 146 pacientes (89 en el grupo 1 y 57 en el grupo 2) y se identificaron un total de 35 eventos hemorrágicos (24% de los pacientes), de los que 12 fueron eventos mayores y 23 menores. La frecuencia de sangrado fue ligeramente mayor en el grupo 1 que en el 2 (25,8% (versus 21%), pero no se encontraron diferencias significativas entre ambos grupos, ni tampoco en la frecuencia de sangrados mayores (10,1% (versus 5,3%; p = 0,235) o menores (13,5% (versus 15,8%; p = 0,496). La frecuencia de eventos hemorrágicos con la dosis de 20 mg fue del 9% (8/89) en el grupo 1 y del 14% (8/57) en el grupo 2 (p = 0,2137), mientras que con una dosis de 15 mg la frecuencia de eventos fue del 16,9% (15/89) en el grupo 1 y del 7% (4/57) en el grupo 2 (p = 0,042).  Conclusiones: No se han hallado diferencias significativas en el riesgo de sangrado según el tipo de inhibidor selectivo de la recaptación de serotonina que se administre de forma concomitante al rivaroxabán. Sí se han observado diferencias significativas en función de la dosis de rivaroxabán utilizada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: The combination of selective serotonin reuptake inhibitors with rivaroxaban may result in a dual interaction (pharmacokinetic and pharmacodynamic) depending on the type of selective serotonin reuptake inhibitor employed (CYP3A4-inhibiting vs. non-CYP3A4 inhibiting). The purpose of this study was to use real world data to determine if the type of selective serotonin reuptake inhibitor used plays a role in the risk and severity of bleeding in patients receiving rivaroxaban.  Method: This was a single-center retrospective longitudinal observational study carried out between January 2016 and February 2020 in patients aged 18 years or older treated concurrently with rivaroxaban (prescribed for treatments) and a selective serotonin reuptake inhibitor. Patients were divided into two groups according to the selective serotonin reuptake inhibitor they received, i.e., a CYP3A4 inhibitor (group 1): sertraline, fluoxetine and paroxetine, or a non-CYP3A4 inhibitor (group 2): citalopram and escitalopram. We analyzed the bleeding events and severity, the daily dose of rivaroxaban used and the medication administered concomitantly.  Results: A total of 146 patients were included (89 in group 1 and 57 in group 2) and 35 bleeding events (24% of patients) were identified, of which 12 were major and 23 were minor. The bleeding rate was higher in group 1 (25.8% vs 21.0%) but there were no differences in major bleeding (10.1% vs 5.3%; p = 0.235) or minor bleeding (13.5% vs 15.8%; p = 0.496). The bleeding rate with a daily rivaroxaban dose of 20 mg was 9% (8/89) in group 1 and 14% (8/57) in group 2 (p = 0.2137), as compared with 16.9% (15/89) in group 1 (versus 7% (4/57) in group 2 (p = 0.042) for a daily 15 mg dose.  Conclusions: Although the type of selective serotonin reuptake inhibitor used concurrently with rivaroxaban was not found to influence the patients' bleeding risk, a significant increase in the risk of bleeding was observed based on the dose of rivaroxaban used.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticoagulantes]]></kwd>
<kwd lng="es"><![CDATA[Hemorragia]]></kwd>
<kwd lng="es"><![CDATA[Rivaroxabán]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores de la recaptación de serotonina]]></kwd>
<kwd lng="es"><![CDATA[Interacciones farmacológicas]]></kwd>
<kwd lng="es"><![CDATA[Seguridad del paciente]]></kwd>
<kwd lng="en"><![CDATA[Anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[Hemorrhage]]></kwd>
<kwd lng="en"><![CDATA[Rivaroxaban]]></kwd>
<kwd lng="en"><![CDATA[Serotonin reuptake inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Pharmacological interactions]]></kwd>
<kwd lng="en"><![CDATA[Patient safety]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hindricks]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Potpara]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dagres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Arbelo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Blomström-Lundqvist]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>373-498</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krijthe]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Kunst]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[OH]]></given-names>
</name>
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2013</year>
<volume>34</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>2746-51</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Abbott]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atrial fibrillation as an independent risk factor for stroke: the Framingham Study]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>1991</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>983-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cha]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Heo]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS 2 and CHA 2DS 2-VASc scores]]></article-title>
<source><![CDATA[Eur J Neurol]]></source>
<year>2012</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>473-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Boriani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chiang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fargo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report]]></article-title>
<source><![CDATA[Chest]]></source>
<year>2018</year>
<volume>154</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1121-201</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[January]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Wann]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Calkins]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Cigarroa]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Cleveland]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>140</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e125-51</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vazquez]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-drug interactions in an era of multiple anticoagulants: A focus on clinically relevant drug interactions]]></article-title>
<source><![CDATA[Hematol (United States)]]></source>
<year>2018</year>
<volume>2018</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>339-47</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clevenger]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Malhotra]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vanle]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[IsHak]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder]]></article-title>
<source><![CDATA[Ther Adv Psychopharmacol]]></source>
<year>2018</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-58</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barua]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Basilio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of depressive disorders in the elderly]]></article-title>
<source><![CDATA[Ann Saudi Med]]></source>
<year>2011</year>
<volume>31</volume>
<page-range>620-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="book">
<collab>American Psychological Association Guideline Development Panel for the Treatment of Depressive Disorders</collab>
<source><![CDATA[Clinical practice guideline for the treatment of depression across three age cohorts]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Washington, DC ]]></publisher-loc>
<publisher-name><![CDATA[American Psychological Association]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fick]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Semla]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Steinman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beizer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dombrowski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults]]></article-title>
<source><![CDATA[J Am Geriatr Soc]]></source>
<year>2019</year>
<volume>67</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>674-94</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemeryck]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Belpaire]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update]]></article-title>
<source><![CDATA[Curr Drug Metab]]></source>
<year>2005</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-37</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrara]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of depression in patients on anticoagulation therapy: Antidepressant-warfarin drug interactions]]></article-title>
<source><![CDATA[US Pharm]]></source>
<year>2013</year>
<volume>38</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>23-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayer]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<source><![CDATA[Xarelto (Ficha técnica)]]></source>
<year></year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[KY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concomitant use of NSAIDs or SSRIs with NOACs requires monitoring for bleeding]]></article-title>
<source><![CDATA[Yonsei MedJ]]></source>
<year>2020</year>
<volume>61</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>741-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheikh Rezaei]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mittlböck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reichardt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wolzt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010-2015]]></article-title>
<source><![CDATA[Int J Geriatr Psychiatry]]></source>
<year>2019</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1194-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Hellkamp]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Hankey]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Berkowitz]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Breithardt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: An analysis from the ROCKET AF trial]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2018</year>
<volume>7</volume>
<numero>15</numero>
<issue>15</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Souverein]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Gardarsdottir]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Van den Ham]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Maitland-van der Zee]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[De Boer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case&#8211;control study]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2020</year>
<volume>86</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1150-64</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaynes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The risks of long-term use of proton pump inhibitors: A critical review]]></article-title>
<source><![CDATA[Ther Adv Drug Saf]]></source>
<year>2018</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vega-Quiroga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo-Pareja]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Medrano]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Louis]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Benito-León]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy in the elderly: A marker of increased risk of mortality in a population- based prospective study (NEDICES)]]></article-title>
<source><![CDATA[Gerontology]]></source>
<year>2015</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>301-9</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[IY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2013</year>
<volume>29</volume>
<numero>7 Suppl</numero>
<issue>7 Suppl</issue>
<page-range>S24-33</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Arroyo]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Madero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Menacho-Miguel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient safety: Prescription of drugs that prolong the QT interval]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2015</year>
<volume>39</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>227-39</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dipiro]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Talbert]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Yee]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Matzke]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmacotherapy: A Physiologic Approach]]></source>
<year>2020</year>
<edition>11ª</edition>
<publisher-loc><![CDATA[Nueva York ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Education/ Medical]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanborn]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sugrue]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Farwati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Deshmukh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common drug interactions of direct oral anticoagulants and their impact on clinical outcomes in atrial fibrillation]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2019</year>
<volume>140</volume>
<numero>Suppl_1</numero>
<issue>Suppl_1</issue>
<page-range>A14420</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
